William Collier Email

President and CEO . Arbutus Biopharma Corporation

Current Roles

Employees:
112
Revenue:
$17.4M
About
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, Arbutus is developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that they intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Arbutus’ lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. Arbutus has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). Arbutus is also exploring oncology applications for its internal PD-L1 portfolio.
Arbutus Biopharma Corporation Address
701 Veterans Circle
Warminster, PA
United States
Arbutus Biopharma Corporation Email
Arbutus Biopharma Corporation Phone Numbers
267-469-0914

Past Companies

Arbutus Biopharma CorporationPresident and Chief Executive Officer
ViiV HealthcarePresident, North America
GSKSVP Office of the CEO

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.